Asfotase alfa submission to FDA for Hypophosphatasia is completed-Alexion Pharma

Alexion Pharmaceuticals has completed its rolling biologics license application submission to the FDA for asfotase alfa as a treatment for Hypophosphatasia (HPP), a chronic and progressive ultra-rare metabolic disease, which can lead to destruction and deformity of bones, profound muscle weakness, seizures, respiratory failure and premature death.